News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
37,873 Results
Type
Article (2420)
Company Profile (39)
Press Release (35414)
Section
Business (14109)
Career Advice (77)
Deals (2075)
Drug Delivery (8)
Drug Development (4092)
Employer Resources (10)
FDA (429)
Job Trends (762)
News (20117)
Policy (1051)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (143)
Allergies (4)
Alliances (3465)
ALS (4)
Alzheimer's disease (44)
Antibody-drug conjugate (ADC) (14)
Approvals (431)
Artificial intelligence (7)
Autoimmune disease (2)
Automation (1)
Bankruptcy (11)
Best Places to Work (476)
BIOSECURE Act (2)
Biosimilars (10)
Biotechnology (29)
Bladder cancer (5)
Brain cancer (5)
Breast cancer (16)
Cancer (109)
Cardiovascular disease (4)
Career advice (64)
Career pathing (1)
CAR-T (14)
Cell therapy (39)
Cervical cancer (2)
Clinical research (3151)
Collaboration (82)
Compensation (40)
COVID-19 (180)
CRISPR (7)
C-suite (22)
Cystic fibrosis (2)
Data (89)
Denatured (3)
Depression (3)
Diabetes (8)
Diagnostics (461)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (12)
Drug pricing (7)
Duchenne muscular dystrophy (9)
Earnings (4182)
Editorial (2)
Employer branding (1)
Employer resources (8)
Events (5956)
Executive appointments (79)
FDA (467)
Featured Employer (3)
Funding (70)
Gene editing (14)
Gene therapy (13)
GLP-1 (59)
Government (149)
Healthcare (702)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (11)
Indications (2)
Infectious disease (185)
Inflammatory bowel disease (11)
Inflation Reduction Act (6)
Influenza (4)
Intellectual property (9)
Interviews (7)
IPO (985)
IRA (7)
Job creations (290)
Job search strategy (62)
Kidney cancer (4)
Labor market (3)
Layoffs (36)
Leadership (1)
Legal (212)
Liver cancer (5)
Lung cancer (15)
Lymphoma (2)
Management (4)
Manufacturing (17)
MASH (3)
Medical device (304)
Medtech (304)
Mergers & acquisitions (1145)
Metabolic disorders (28)
Multiple sclerosis (6)
Neurodegenerative disease (7)
Neuropsychiatric disorders (3)
Neuroscience (85)
NextGen: Class of 2025 (352)
Non-profit (153)
Northern California (307)
Now hiring (4)
Obesity (14)
Opinion (15)
Ovarian cancer (9)
Pain (7)
Pancreatic cancer (2)
Parkinson's disease (4)
Partnered (1)
Patents (16)
Patient recruitment (2)
Peanut (1)
People (5604)
Pharmaceutical (5)
Phase I (1358)
Phase II (1582)
Phase III (841)
Pipeline (48)
Podcasts (4)
Policy (10)
Postmarket research (30)
Preclinical (583)
Press Release (2)
Prostate cancer (3)
Psychedelics (2)
Radiopharmaceuticals (12)
Rare diseases (19)
Real estate (419)
Recruiting (5)
Regulatory (792)
Reports (6)
Research institute (142)
Resumes & cover letters (9)
Schizophrenia (10)
Series A (21)
Series B (4)
Service/supplier (2)
Sickle cell disease (1)
Southern California (306)
Special edition (1)
Sponsored (1)
Startups (487)
Stomach cancer (1)
Supply chain (3)
The Weekly (1)
United States (1474)
Vaccines (25)
Venture capitalists (6)
Webinars (2)
Weight loss (9)
Women's health (1)
Worklife (1)
Date
Today (18)
Last 7 days (56)
Last 30 days (229)
Last 365 days (2577)
2025 (432)
2024 (2610)
2023 (2859)
2022 (3751)
2021 (4048)
2020 (3471)
2019 (2061)
2018 (1554)
2017 (1795)
2016 (1624)
2015 (1833)
2014 (1369)
2013 (1188)
2012 (1396)
2011 (1332)
2010 (1181)
Location
Africa (43)
Alabama (1)
Arizona (14)
Asia (1848)
Australia (296)
California (704)
Canada (122)
China (32)
Colorado (17)
Connecticut (10)
Delaware (3)
Europe (3792)
Florida (41)
Georgia (4)
Idaho (3)
Illinois (14)
India (1)
Indiana (28)
Japan (7)
Kansas (12)
Maryland (23)
Massachusetts (251)
Michigan (8)
Minnesota (14)
Missouri (3)
Nebraska (1)
Nevada (2)
New Hampshire (1)
New Jersey (56)
New York (41)
North Carolina (82)
Northern California (307)
Ohio (24)
Oklahoma (2)
Oregon (4)
Pennsylvania (34)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (306)
Tennessee (2)
Texas (59)
Utah (2)
Virginia (5)
Washington D.C. (1)
Washington State (39)
Wisconsin (5)
37,873 Results for "intervenn biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO
InterVenn Biosciences, the life sciences company pioneering glycoproteomic-based diagnostics, announced that Joshua Stahl has been appointed as Chief Executive Officer to guide the company’s next phase of commercial growth.
September 27, 2023
·
3 min read
Biotech Bay
InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology, the Flagship Journal of the American Gastroenterological Association
InterVenn Biosciences, a life sciences company pioneering glycoproteomics, announced the publication of their discovery work in Advanced Adenoma and Colorectal Cancer early disease detection in the flagship journal of the American Gastroenterological Association, Gastroenterology.
October 13, 2023
·
5 min read
Biotech Bay
InterVenn Biosciences to Present Clinical Data on Circulating Serum Glycoproteins for Unprecedented Pre-Cancer Detection as “Poster of Distinction” at Digestive Disease Week 2023
InterVenn Biosciences today announced new clinical data that demonstrates the power of InterVenn’s proprietary biomarker discovery platform, GlycoVision™ , to detect advanced adenomas (AA) and colorectal cancer (CRC).
April 19, 2023
·
4 min read
Business
InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization
InterVenn Biosciences today announced changes to its senior management team to support its commercialization execution.
January 5, 2023
·
5 min read
Biotech Bay
InterVenn Demonstrates Power of Its GlycoVision™ Platform In Advanced Adenoma and Colorectal Cancer
InterVenn Biosciences, the life science company pioneering glycoproteomics, presented new data at the 2023 Digestive Disease Week (DDW) annual conference, which was honored as a “Poster of Distinction”.
May 8, 2023
·
3 min read
Business
Erwin Estigarribia is Appointed President and Chief Operating Officer of InterVenn Biosciences
InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that Erwin Estigarribia has been appointed President and Chief Operating Officer, effective immediately.
October 26, 2022
·
4 min read
Business
InterVenn Biosciences Co-Founder Carolyn Bertozzi Awarded Nobel Prize in Chemistry
InterVenn Biosciences announced that its co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in chemistry.
October 5, 2022
·
3 min read
Biotech Bay
InterVenn Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
InterVenn Biosciences today announced that senior management will present at the J.P. Morgan 41st annual Healthcare Conference on January 11, 2023 at 8:30 a.m. Pacific.
January 3, 2023
·
1 min read
Biotech Bay
InterVenn Biosciences Announces Start of Enrollment in Colonoscopy Study
InterVenn® Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced the start of enrollment in its prospective cohort study for early detection of colorectal cancer and adenomas.
August 2, 2022
·
4 min read
Biotech Bay
InterVenn Biosciences to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
InterVenn Biosciences today announced Company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 17, 2022 at 2:30 p.m. Eastern Time.
November 10, 2022
·
1 min read
1 of 3,788
Next
